Vita Life Sciences Limited
Vita Life Sciences Limited Fundamental Analysis
Vita Life Sciences Limited (VLS.AX) shows strong financial fundamentals with a PE ratio of 13.42, profit margin of 11.19%, and ROE of 19.15%. The company generates $0.1B in annual revenue with strong year-over-year growth of 17.31%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 74.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze VLS.AX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentVLS.AX demonstrates superior asset utilization.
Valuation Score
ExcellentVLS.AX trades at attractive valuation levels.
Growth Score
ExcellentVLS.AX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentVLS.AX maintains a strong and stable balance sheet.
Profitability Score
ModerateVLS.AX maintains healthy but balanced margins.
Key Financial Metrics
Is VLS.AX Expensive or Cheap?
P/E Ratio
VLS.AX trades at 13.42 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, VLS.AX's PEG of 1.14 indicates fair valuation.
Price to Book
The market values Vita Life Sciences Limited at 2.49 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.49 times EBITDA. This signals the market has high growth expectations.
How Well Does VLS.AX Make Money?
Net Profit Margin
For every $100 in sales, Vita Life Sciences Limited keeps $11.19 as profit after all expenses.
Operating Margin
Core operations generate 15.71 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.15 in profit for every $100 of shareholder equity.
ROA
Vita Life Sciences Limited generates $12.67 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Vita Life Sciences Limited produces operating cash flow of $15.72M, showing steady but balanced cash generation.
Free Cash Flow
Vita Life Sciences Limited generates strong free cash flow of $15.18M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.28 in free cash annually.
FCF Yield
VLS.AX converts 11.83% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.42
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.14
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.49
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.44
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.08
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.72
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.25
vs 25 benchmark
How VLS.AX Stacks Against Its Sector Peers
| Metric | VLS.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.42 | 28.54 | Better (Cheaper) |
| ROE | 19.15% | 738.00% | Weak |
| Net Margin | 11.19% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.08 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.72 | 2806.01 | Strong Liquidity |
| ROA | 12.67% | -14624.00% (disorted) | Strong |
VLS.AX outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Vita Life Sciences Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
88.50%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
60.86%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
104.54%
Industry Style: Defensive, Growth, Innovation
High Growth